BiotechTube

QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent Asthma

Conditions

Persistent Asthma

Trial Timeline

Nov 1, 2010 → Sep 1, 2011

NCT ID
NCT01253603

About QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days

QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days is a phase 2 stage product being developed by Novartis for Persistent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01253603. Target conditions include Persistent Asthma.

What happened to similar drugs?

4 of 8 similar drugs in Persistent Asthma were approved

Approved (4) Terminated (1) Active (4)
✅Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
✅RivastigmineNovartisApproved
✅Omalizumab + PlaceboNovartisApproved
✅irbesartan + placeboSanofiApproved
🔄E7777 9 mcg/kgEisaiPhase 3
🔄CertoparinNovartisPhase 3
🔄Omalizumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01253603Phase 2Completed

Competing Products

20 competing products in Persistent Asthma

See all competitors
ProductCompanyStageHype Score
E7777 9 mcg/kgEisaiPhase 3
40
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
29
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
35
AZD0837 + AspirinAstraZenecaPhase 2
35
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
26
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
35
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
35
CertoparinNovartisPhase 3
40
Omalizumab + PlaceboNovartisPhase 3
40
RivastigmineNovartisApproved
43
Indacaterol + Placebo to IndacaterolNovartisPhase 2
35
Omalizumab + PlaceboNovartisApproved
43
placebo + iv sildenafilPfizerPhase 3
40
etanercept + placeboPfizerPhase 2
35
SildenafilPfizerPhase 2
27
irbesartan + placeboSanofiApproved
39
iloprostBayerPre-clinical
15
IV Remodulin + PlaceboUnited TherapeuticsPhase 2
24
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)GlaukosPhase 2
24